ABEONA THERAPEUTICS INC. Share-based Payment Arrangement, Expense, after Tax
ABEONA THERAPEUTICS INC. (ABEO) reported Share-based Payment Arrangement, Expense, after Tax of $5.25 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2022-03-31
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for the quarter ending 2020-06-30 was $1.58M, a 5.96% decline year-over-year.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for the quarter ending 2019-12-31 was $1.73M.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for the quarter ending 2019-09-30 was $1.83M, a 26.93% decline year-over-year.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for the quarter ending 2019-06-30 was $1.68M.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for fiscal 2021 was $5.25M, a 10.30% decline from fiscal 2020.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for fiscal 2020 was $5.85M, a 20.24% decline from fiscal 2019.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for fiscal 2019 was $7.34M.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, expense, after tax for fiscal 2015 was $4.37M, a 234.71% increase from fiscal 2014.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | $5.25M 10-K · filed 2022-03-31 | |||
| 2020-12-31 | $5.85M 10-K · filed 2022-03-31 | |||
| 2020-06-30 | $1.58M 10-Q · filed 2020-08-10 | $2.83M 10-Q · filed 2020-08-10 | ||
| 2019-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $3.56M derived: sum of 2 quarters · filed 2021-03-24 | $5.24M derived: sum of 3 quarters · filed 2021-03-24 | $7.34M 10-K · filed 2021-03-24 |
| 2019-09-30 | $1.83M 10-Q · filed 2019-11-12 | $3.50M derived: sum of 2 quarters · filed 2020-08-10 | $5.61M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.68M 10-Q · filed 2020-08-10 | $3.78M 10-Q · filed 2020-08-10 | ||
| 2018-09-30 | $2.50M 10-Q · filed 2019-11-12 | $7.07M 10-Q · filed 2019-11-12 | ||
| 2015-12-31 | $4.37M 10-K · filed 2016-03-30 | |||
| 2014-12-31 | $1.30M 10-K · filed 2016-03-30 | |||
| 2013-12-31 | $439.00K 10-K · filed 2015-03-31 | |||
| 2012-12-31 | $390.00K 10-K · filed 2014-03-26 | |||
| 2011-12-31 | $1.07M 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |